a public good project by the
Synthesis
Company
of California

© 2026

Masafumi Ikeda | doi.page

0 works0 citations0 h-index

Masafumi Ikeda

National Cancer Center Hospital East(JP)

Publications by Year

Research Areas

Pancreatic and Hepatic Oncology Research, Hepatocellular Carcinoma Treatment and Prognosis, Cholangiocarcinoma and Gallbladder Cancer Studies, Colorectal Cancer Treatments and Studies, Neuroendocrine Tumor Research Advances

Most-Cited Works

→ Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma(2020)6,911 cited
→ Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma(2021)1,517 cited
→ Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma(2020)1,150 cited
→ Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer(2022)1,014 cited
→ Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial(2019)694 cited
→ Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update(2021)643 cited

→ Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study(2013)629 cited

→ JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan(2014)629 cited

→ Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin(2004)615 cited

→ Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study(2020)559 cited